BD Tau Workflow

About Roboscreen

Roboscreen GmbH is a privately held, revenue-generating diagnostics company with over two decades of experience in developing molecular and immunochemical tests. Its core business revolves around two key areas: viral pathogen detection (Hepatitis B, C, Delta) and biomarkers for neurodegenerative diseases. Following a management buyout from Analytik Jena AG in 2020, the company operates independently but maintains strategic partnerships, holding ISO 13485 certification and distributing its products globally through a network of partners. Roboscreen actively engages in scientific collaborations and conference presentations to advance its diagnostic toolbox.

Therapeutic Areas